On the basis of the results obtained from the CT26 and Hepa1-6 tumor models, here, we propose a model to describe the antitumor activity mediated by genetic reprogramming of TAM by exoASO-STAT6 (Fig. 7). The gene discussed is STAT6; the disease is neoplasm.